Mesalamine Formulations
Disclosed are oral dosage forms comprising an effective amount of mesalamine, wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution test comprising stirring in a pH 6.0 solution for 1 hour, followed by stirring in a pH 7.2 solution for an additional hour. In some embodiments, the dosage form releases less than all of the mesalamine to the right side of the colon. Release of less than all of the mesalamine dosage form to the right side of the colon may be determined by the in vitro dissolution profile of the dosage form.
1 . A mesalamine dosage form comprising
an effective amount of mesalamine,
wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution test comprising stirring in a pH 6.0 solution for 1 hour, followed by stirring in a pH 7.2 solution for an additional hour.
2 . The mesalamine dosage form of claim 1 , wherein the dosage form comprises a core comprising the effective amount of mesalamine, and a coating disposed on the core, the coating being soluble in aqueous solution at a pH of greater than or equal to 5.5 to less than 7.0.
3 . The dosage form of claim 2 , wherein the coating comprises
0-30% of a polymer soluble at pH>7.0; and
70-100% of a polymer soluble at pH≧5.5.
4 . The dosage form of claim 2 , wherein the coating comprises
0-30% of an anionic copolymer of methacrylic acid, methylacrylate and methyl methacrylate in which the ratio of free carboxyl groups to ester groups is about 1:10; and
70-100% of an anionic copolymer of methacrylic acid and ethyl acrylate in which the ratio of free carboxyl groups to ester groups is about 1:1.
5 . The mesalamine dosage form of claim 1 , wherein 5 wt % to about 35 wt % of the mesalamine dissolves in the pH 6.0 portion of the dissolution test, and about 65 wt % to 95 wt % of the mesalamine dissolves in the pH 7.2 portion of the dissolution test.
6 . A mesalamine dosage form comprising
a core comprising an effective amount of mesalamine, wherein the core does not include a carbonate; and
a coating disposed on the core, the coating being soluble in aqueous solution at a pH of greater than or equal to 5.5 to less than 7.0, and
wherein the coating does not include a quaternary ammonium substituted acrylic polymer.
7 . The mesalamine dosage form of claim 6 , wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution test comprising stirring in a pH 6.0 solution for 1 hour, followed by stirring in a pH 7.2 solution for an additional hour.
8 . The mesalamine dosage form of claim 7 , wherein 5 wt % to about 35 wt % of the mesalamine dissolves in the pH 6.0 portion of the dissolution test, and about 65 wt % to 95 wt % of the mesalamine dissolves in the pH 7.2 portion of the dissolution test.
9 . The dosage form of claim 6 , wherein the coating comprises
0-30% of a polymer soluble at pH>7.0; and
70-100% of a polymer soluble at pH≧5.5.
10 . The dosage form of claim 6 , wherein the coating comprises
0-30% of an anionic copolymer of methacrylic acid, methylacrylate and methyl methacrylate in which the ratio of free carboxyl groups to ester groups is about 1:10; and
70-100% of an anionic copolymer of methacrylic acid and ethyl acrylate in which the ratio of free carboxyl groups to ester groups is about 1:1.
11 . The dosage form of claim 6 , wherein the coating comprises 3-15% by weight of the dosage form.
12 . The dosage form of claim 7 , wherein the dosage form has a dissolution profile such that at least 10 wt % of the total weight of the mesalamine in the dosage form is released during the pH 6.0 portion of the dissolution test.
13 . The dosage form of claim 7 , wherein the dosage form has a dissolution profile such that at least 20 wt % of the total weight of the mesalamine in the dosage form is released during the pH 6.0 portion of the dissolution test.
14 . A method of treating an individual in need of treatment for ulcerative colitis, comprising administering to the individual the dosage form of claim 1 .
15 . The method of claim 14 , wherein the dosage form comprises 400 mg to 800 mg of mesalamine.
16 . The method of claim 14 , wherein the dosage form is administered at a daily dosage of 2.4 g/day or 4.8 g/day.
17 . The method of claim 14 , wherein the dosage form comprises a core comprising the effective amount of mesalamine, and a coating disposed on the core, the coating being soluble in aqueous solution at a pH of greater than or equal to 5.5 to less than 7.0.
18 . The method of claim 14 , wherein the coating comprises
0-30% of a polymer soluble at pH>7.0; and
70-100% of a polymer soluble at pH≧5.5.